Global Lenacapavir Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Lenacapavir market size was valued at US$ 154 million in 2025 and is forecast to a readjusted size of US$ 1794 million by 2032 with a CAGR of 13.9% during review period.
Lenacapavir is a long-acting HIV-1 capsid inhibitor that exerts its antiviral effect by specifically binding to the viral capsid protein, thereby blocking the assembly, release, and uncoating processes of HIV and ultimately inhibiting viral replication. Characterized by its novel mechanism of action, prolonged half-life, and reduced dosing frequency, it is indicated both for the treatment of adults with multidrug-resistant HIV-1 infection and as a long-acting agent for pre-exposure prophylaxis (PrEP). By offering a novel option for the treatment and prevention of HIV/AIDS, it is particularly beneficial for patients with suboptimal responses to conventional regimens or those with poor medication adherence.In 2025, global Lenacapavir production reached approximately 450,000 vials (注射液) and 300,000 bottles（片剂）
Lenacapavir is the world’s first long-acting HIV-1 capsid inhibitor administered only twice yearly. With its disruptive mechanism of action, exceptional clinical efficacy, and extremely low dosing frequency, it is comprehensively reshaping the market landscape for HIV/AIDS treatment and prevention. Its core advantage lies in fundamentally resolving the long-standing challenge of patient adherence associated with traditional daily oral regimens, while also demonstrating potent inhibitory activity against multidrug-resistant viral strains. It serves both as a vital salvage therapy for advanced patients with treatment failure and opens up a highly effective and convenient new avenue for pre-exposure prophylaxis (PrEP) in at-risk populations. Against the backdrop of sustained strong global demand for HIV prevention and treatment, the drug has rapidly secured a strong market position through its differentiated product strengths, competing directly with similar products especially in the long-acting prevention sector and leading the industry’s paradigm shift from daily medication to long-acting injection. However, its market expansion faces significant challenges: the prohibitively high pricing of the originator drug severely limits accessibility in middle- and high-income countries. Although generic drug promotion via patent licensing in low- and middle-income countries has expanded coverage, price stratification, regional access disparities, and supply chain development remain core constraints to its global penetration. Overall, with its breakthrough clinical value and innovative positioning, lenacapavir has emerged as a high-growth blockbuster product in the HIV field, and its future market performance will be highly dependent on pricing strategies, insurance coverage, and collaborative advancement of global public health resources.
This report is a detailed and comprehensive analysis for global Lenacapavir market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Lenacapavir market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Lenacapavir market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Lenacapavir market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Lenacapavir market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Lenacapavir
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Lenacapavir market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, WuXi AppTec, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Lenacapavir market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
0.3 g
1.5 mL
Market segment by Dosage Form
Tablets
Injection
Market segment by Route of Administration
Oral Administration
Subcutaneous Injection
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Multidrug-Resistant HIV-1 Infection
Treatment Of HIV Infection In Adults
Others
Major players covered
Gilead Sciences
WuXi AppTec
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Lenacapavir product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Lenacapavir, with price, sales quantity, revenue, and global market share of Lenacapavir from 2021 to 2026.
Chapter 3, the Lenacapavir competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Lenacapavir breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Lenacapavir market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Lenacapavir.
Chapter 14 and 15, to describe Lenacapavir sales channel, distributors, customers, research findings and conclusion.